Can you get tirzepatide in a pill form — and does it exist in the UK?

You found this page because something made you think a tirzepatide tablet exists

Maybe it was a headline about an oral GLP-1. Maybe a forum post mentioned a pill. Possibly someone compared Mounjaro with Wegovy tablets and the names blurred together. It happens constantly, and it is not a daft assumption, the GLP-1 space has moved quickly in 2026, and a genuinely new oral option has just arrived.

Here is what is actually happening. Wegovy, Novo Nordisk's semaglutide brand, received MHRA approval in tablet form on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 specifically for weight management. Mounjaro (Eli Lilly's tirzepatide) has not followed that path. No oral tirzepatide product exists anywhere at regulatory level. The two brands are sometimes discussed side by side because both treat obesity and both work on GLP-1 receptors, but tirzepatide also activates the GIP receptor, which semaglutide does not. Those structural differences matter for development too; they are not interchangeable molecules.

Eli Lilly is researching oral small-molecule GLP-1 medicines, but those are distinct chemical compounds, not tirzepatide in capsule form. If you want detail on what Mounjaro is and how it works as an injection, our Mounjaro overview covers the mechanism, the licensed uses and the injection schedule. For now, if the injection route genuinely puts you off, you have a real alternative to explore.

Why tirzepatide cannot simply be put into a tablet, and what oral semaglutide did differently

Tirzepatide is a large peptide molecule. Swallowed whole, it would meet the same fate as many proteins: digestive enzymes and stomach acid break it apart before it can cross the gut wall and enter the bloodstream. The injection format sidesteps that entirely by delivering the medicine subcutaneously, where it is absorbed slowly and predictably over the week.

Oral semaglutide has been around for years in the diabetes context (as Rybelsus), and Novo Nordisk's engineers solved the absorption problem by co-formulating semaglutide with a compound called SNAC, which temporarily changes the local pH around the tablet and allows a usable fraction of the peptide to be absorbed. Even then, it requires a specific morning ritual: first thing on an empty stomach, a small sip of plain water, and at least 30 minutes before any food, coffee or other tablets. The absorption window is narrow. If you are wondering whether there is a pill form of tirzepatide, the short answer is that the molecule's structure makes a similar formulation considerably more difficult, not impossible in principle, but not solved yet.

The full explainer on tirzepatide in pill form goes deeper into the pharmaceutical chemistry for anyone who wants that level of detail. For most people, the practical summary is: Mounjaro in pill form is not something that currently exists, and an oral alternative exists, just not from the same molecule. You can read more about how these tirzepatide facts compare on our main tirzepatide reference page.

What your actual options look like right now, injection versus tablet

If needle aversion is the driver behind the search, the Wegovy tablet is a meaningful option. It was approved based on the OASIS 4 phase-3 trial (307 adults, 64 weeks), which found an average weight reduction of around 13.6% versus about 2.4% for placebo. Among participants who adhered fully to the treatment schedule, that figure reached around 17%, though that fully-adherent figure needs the context it comes with; it is not a guaranteed average. The MHRA approval is documented on GOV.UK.

Mounjaro injection, by contrast, showed average weight reductions of around 20–21% at the highest dose over 72 weeks in SURMOUNT-1, and produced greater average loss than semaglutide 2.4mg in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025. Those are meaningful differences. For someone comfortable with a once-weekly self-injection (which most patients find straightforward after the first one) Mounjaro's clinical track record is stronger on current evidence.

The choice between the two is a clinical one, shaped by your health history, any contraindications, your preferences and what your prescriber thinks fits. Our team reviews every consultation personally; you can explore both routes on the weight-loss treatments overview. One useful note: the Wegovy tablet has no refrigeration requirement, which matters for some people. Mounjaro pens are stored in the fridge, which is routine for most households, the pen sits in the fridge door, same as any other injectable medicine, and you take it out a few minutes before use. Neither format requires special equipment.

On cost, treatment pricing varies by dose and provider and changes as the market moves. Our Mounjaro pricing page has current context, and the same is true of the Wegovy tablet. One thing to know about any private weight-loss prescription: a legitimately priced service covers the clinical consultation and prescription, not just the medicine itself. The FAQs cover common questions about both formats if you want to read more before deciding.